Loading clinical trials...
Loading clinical trials...
A Phase 1, Dose Escalation Study Of Pf-06664178 In Patients With Locally Advanced Or Metastatic Solid Tumors
To assess the safety and tolerability at increasing dose levels of PF-06664178 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Keck Hospital of USC
Los Angeles, California, United States
LAC&USC Medical Center
Los Angeles, California, United States
USC/Norris Comprehensive Cancer Center / Investigational Drug Services
Los Angeles, California, United States
USC/Norris Comprehensive Cancer Center
Los Angeles, California, United States
Anschutz Cancer Pavilion
Aurora, Colorado, United States
University of Colorado Denver CTO (CTRC)
Aurora, Colorado, United States
University of Colorado Hospital
Aurora, Colorado, United States
Swedish Medical Center
Seattle, Washington, United States
Seattle Cancer Care Alliance
Seattle, Washington, United States
University of Washington Medical Center
Seattle, Washington, United States
Start Date
August 1, 2014
Primary Completion Date
June 1, 2016
Completion Date
June 1, 2016
Last Updated
February 19, 2018
31
ACTUAL participants
PF-06664178
DRUG
PF-06664178
DRUG
Lead Sponsor
Pfizer
NCT00026884
NCT07159659
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07213804